Short answer
Solid Biosciences Inc. (SLDB) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$57M
- −44.4% YoY
- EPS (diluted)
- −$0.52
- +11.9% YoY
Source: XBRL data from the Solid Biosciences Inc. (SLDB) Q1 2026 10-Q on SEC EDGAR. USD.
Solid Biosciences Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no commercial product revenue generated
- Net loss $56.7M vs $39.3M, up 44.4% YoY; operating margin figures not disclosed
- Highest R&D program SGT-003 at $22.9M, up 146.7% YoY
- Cash, equivalents and securities $380.7M at March 31, 2026; funding expected into first half of 2028
- R&D expense $46.1M, up 49.3% YoY; continued trial spending and potential trade, tariff and supply-chain headwinds
Risk Factors
- Newly disclosed Grade 3 immune-mediated myositis in INSPIRE DUCHENNE, identified as treatment-related by May 11, 2026
- Clinical development risk heightened by one prior FDA clinical hold and inability to guarantee similar future interruptions
- Preclinical supply risk from constrained non-human primate sourcing, potentially delaying IND-enabling studies
- Liquidity runway extends into first half of 2028, but additional funding remains necessary thereafter
- Operating loss $56.7 million in Q1 2026 versus $39.3 million in Q1 2025, with accumulated deficit of $1.0 billion
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Solid Biosciences Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.